EquitiesMedium impact
Spyre Therapeutics (SYRE) Plummets 14.3% Pre-Market Amid Market Caution
gurufocus.com·5 days ago·Global·1 min read
Rigense market context
Equities
No image available. Showing a neutral Rigense placeholder.
On August 26, 2026, Spyre Therapeutics Inc (SYRE) saw a sharp pre-market decline of 14.3% as investors brace for Nvidia's earnings and key economic data release
Related news
Equities
PRTH Looks 7.3% Undervalued on GF Value™
gurufocus.com
Equities
AeroVironment wins $51M U.S. Army Switchblade 600 order (NASDAQ:AVAV)
seekingalpha.com
Equities
Better and Coinbase launch token-backed, conforming mortgage (BETR:NASDAQ)
seekingalpha.com
Equities
Abercrombie & Fitch Co. 2026 Q2 - Results - Earnings Call Presentation (NYSE:ANF) 2026-08-26
seekingalpha.com
Equities
Cathie Wood Isn't Backing Away From SpaceX Stock
gurufocus.com
Equities
META Looks 32.4% Undervalued on GF Value™ Amid Workforce Restructuring
gurufocus.com